Table 3. Comparison of immune cells in patients (severe and moderate cases) and controls.
| Immune cells | Median (/μL) (IQR) | P* | Median (/μL) (IQR) | P* | ||
|---|---|---|---|---|---|---|
| Patients | Control | Moderate cases | Severe cases | |||
| CD3+ | 485 (320–882) | 1730 (1343–2435) | 0.001 | 522 (389–1054) | 368 (202–635) | 0.009 |
| CD4+ | 283 (184–575) | 1111 (883–1703) | <0.001 | 330 (200–652) | 226 (120–413) | 0.016 |
| CD8+ | 182 (100–319) | 607 (421–803) | <0.001 | 184 (116–340) | 130 (79–307) | 0.115 |
| CD16+ | 113 (56–173) | 304 (205–456) | <0.001 | 135 (82–174) | 71 (46–158) | 0.011 |
| CD20+ | 123 (54–246) | 293 (229–409) | <0.001 | 132 (58–248) | 100 (47–194) | 0.244 |
| CD16+CD56+ | 28 (16–52) | 41 (25–84) | 0.06 | 31 (18–68) | 22 (12–33) | 0.066 |
*Independent T-test.